Abstract 255P
Background
MEX3A is an evolutionarily conserved RNA-binding protein (RBP), of which functions and target genes in mammals remain largely unknown. Also, no previous study has shown the role of MEX3A in endometrial cancer.
Methods
We screened the differentially expressed genes (DEGs) and miRNAs (DEmiRs) between endometrial cancer samples and paired adjacent noncancerous endometrium samples with RNA-seq data. Then, we used package clusterProfiler to profile the GO and KEGG enrichment analysis of the most highly correlated genes with MEX3A, as well as the overlap genes with up-regulated DEGs. We evaluated the prognostic effect of genes using the Kaplan-Meier Plotter database. MEX3A tissue-specific expression was analyzed via the Human Protein Atlas database and TIMER. Methylation analysis was generated by MethHC and Wanderer.
Results
The volcano plot of DEmiRs showed a significant reduction in tumor suppressor miR-139 in tumor tissues compared to normal tissues. We totally identified 422 target genes of miR-139-5p using the prediction software TargetScan (7.1 version). MEX3A was one of the seven overlapping genes that we got between the miRNA target genes and the 842 up-regulated DEGs. MEX3A was significantly overexpressed in many types of tumor tissues, and interestingly, it had the highest expression in the female tissues. In addition, high MEX3A expression was significantly correlated with poor OS and progression-free survival (PFS) in endometrial cancers (OS HR = 2.07, P = 0.0021; PFS HR = 2.11, P = 0.0047). The GO analysis of top 5% most highly correlated genes with MEX3A in endometrial cancer revealed that biology processes associated with RNA splicing were mainly enriched. Simultaneously, the most enriched pathway was spliceosome, which indicated that the RBP may play an important role in the RNA splicing. Meanwhile, the MEX3A promoter region in the tumor tissue was hypomethylated compared to normal tissue. In addition, the MEX3A promotor differential methylation level is negatively correlated with MEX3A mRNA expression (corr = -0.512).
Conclusions
These findings suggest MEX3A is a potential prognostic biomarker in endometrial cancer and might play an oncogenic role as a novel cancer-critical splicing factor.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
The author has declared no conflicts of interest.
Resources from the same session
154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study
Presenter: Krithika Murali
Session: Poster display session
Resources:
Abstract
155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?
Presenter: Girish M. S
Session: Poster display session
Resources:
Abstract
156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Presenter: Zhen Xiang
Session: Poster display session
Resources:
Abstract
157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy
Presenter: Jitin Yadav
Session: Poster display session
Resources:
Abstract
158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer
Presenter: Kim Jinkook
Session: Poster display session
Resources:
Abstract
159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016
Presenter: Hee Man Kim
Session: Poster display session
Resources:
Abstract
160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Presenter: Jooyoung Ha
Session: Poster display session
Resources:
Abstract
161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival
Presenter: In Young Jo
Session: Poster display session
Resources:
Abstract
163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma
Presenter: Thanachai Sanlung
Session: Poster display session
Resources:
Abstract